GlassScriptPhysician profile
Taylor C Read
NPI 1144870007
$852.32
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.31 · 2023: $481 · 2024: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $214.58 | 2022-2024 | |
| Boston Scientific Corporation | $106.35 | 2023-2024 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $96.40 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $74.65 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.95 | 2023-2024 | Jardiance |
| Amgen INC. | $49.62 | 2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.15 | 2023-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $46.46 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $42.91 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $30.08 | 2023 | Opsumit |
| Irhythm Technologies, INC. | $29.47 | 2023 | Zio Xt Patch |
| Abiomed | $24.16 | 2024 | Impella |
| Alnylam Pharmaceuticals INC. | $14.43 | 2023 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $14.11 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Read listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.